The 3D Printed Drugs market is anticipated to witness lucrative growth in the near future. The ease of ingestion of drug for the patients suffering from several diseases causing seizures such as epilepsy, medicinal intake by old age and infants are several applications of 3D printed drugs effecting the 3D Printed Drugs market in forth coming years.
Asia Pacific is slated to account for a leading share of 34.1% by 2024 in the 3D printed drugs market and expected to witness lucrative growth over the forecast period i.e. 2018-2024 by registering a CAGR of 18.2% over the forecast period. Further, the market is expected to account for USD 532 Million by 2024 from USD 142.8 Million in 2016. This can be attributed to the robust expansion of pharmaceutical industries in this the region on the back of positive GDP figures. Further, rising adoption of advanced healthcare technologies by consumers on the back of swelled disposable income is expected to positively drive the growth of the market.
In addition to this, China 3D printed drugs market was held at USD 67.3 Million in 2016 and is anticipated to reach USD 252 Million by the end of 2024. China 3D printed drugs market accounted for a market share of 47.17% in 2016 and further, is expected to increase to a market share of 47.37% by the end of 2024.
North America 3D printed drugs market expected to witness lucrative growth over the forecast period i.e. 2018-2024 by registering a CAGR of 19.4% over the forecast period.
Global 3D printed drugs market is segmented on the basis of application into orthopedic, neurology, hearing & audibility aid, medical implants, dental and others. Among these segments, Neurology segment (37.1% share in 2016) occupies the largest market of 3D printed drugs across the globe. Further, global Neurology segment is anticipated to reach USD 594.6 Million by the end of 2024 from USD 156.6 Million in 2016
FabRx Ltd. Technologies Inc., Aprecia Pharmaceuticals, LLC. are the only players of 3D printed drugs market and GlaxoSmithKline (GSK) is considered to be a potential player as the organization is contemplating to invest considerably in the industry.
Asia Pacific is slated to account for a leading share of 34.1% by 2024 in the 3D printed drugs market and expected to witness lucrative growth over the forecast period i.e. 2018-2024 by registering a CAGR of 18.2% over the forecast period. Further, the market is expected to account for USD 532 Million by 2024 from USD 142.8 Million in 2016. This can be attributed to the robust expansion of pharmaceutical industries in this the region on the back of positive GDP figures. Further, rising adoption of advanced healthcare technologies by consumers on the back of swelled disposable income is expected to positively drive the growth of the market.
In addition to this, China 3D printed drugs market was held at USD 67.3 Million in 2016 and is anticipated to reach USD 252 Million by the end of 2024. China 3D printed drugs market accounted for a market share of 47.17% in 2016 and further, is expected to increase to a market share of 47.37% by the end of 2024.
North America 3D printed drugs market expected to witness lucrative growth over the forecast period i.e. 2018-2024 by registering a CAGR of 19.4% over the forecast period.
Global 3D printed drugs market is segmented on the basis of application into orthopedic, neurology, hearing & audibility aid, medical implants, dental and others. Among these segments, Neurology segment (37.1% share in 2016) occupies the largest market of 3D printed drugs across the globe. Further, global Neurology segment is anticipated to reach USD 594.6 Million by the end of 2024 from USD 156.6 Million in 2016
FabRx Ltd. Technologies Inc., Aprecia Pharmaceuticals, LLC. are the only players of 3D printed drugs market and GlaxoSmithKline (GSK) is considered to be a potential player as the organization is contemplating to invest considerably in the industry.
Table of Contents
1. Executive Summary2. Research Methodology3. Global 3D Printed Drugs Market Size (USD Million) and Forecast, 2017-2024
4. Market Dynamics & Its Impact Analysis
5. Global Market Segmentation Analysis
7. Competitive Landscape
Companies Mentioned
- Apprecia Pharmaceuticals
- FabRx Ltd
- GlaxoSmithKline
